Rock Springs Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-10,100
Closed -$7.8M 113
2026
Q1
$7.8M Hold
10,100
0.46% 54
2025
Q4
$7.8M Sell
10,100
-1,200
-11% -$815K 0.4% 58
2025
Q3
$6.35M Hold
11,300
0.37% 62
2025
Q2
$5.93M Buy
11,300
+8,500
+304% +$4.74M 0.37% 60
2025
Q1
$1.78M Buy
+2,800
New +$1.93M 0.1% 79
2017
Q4
Sell
-16,000
Closed -$7.15M 150
2017
Q3
$7.15M Hold
16,000
0.33% 89
2017
Q2
$7.86M Buy
16,000
+900
+6% +$394K 0.4% 76
2017
Q1
$5.85M Sell
15,100
-4,400
-23% -$1.63M 0.34% 84
2016
Q4
$7.16M Buy
19,500
+2,500
+15% +$951K 0.48% 59
2016
Q3
$6.83M Hold
17,000
0.43% 66
2016
Q2
$5.94M Buy
17,000
+500
+3% +$193K 0.44% 75
2016
Q1
$5.95M Buy
16,500
+5,500
+50% +$2.27M 0.5% 68
2015
Q4
$5.97M Hold
11,000
0.45% 74
2015
Q3
$5.12M Hold
11,000
0.42% 78
2015
Q2
$5.61M Buy
11,000
+1,000
+10% +$488K 0.41% 82
2015
Q1
$4.51M Buy
10,000
+1,000
+11% +$424K 0.42% 75
2014
Q4
$3.69M Buy
+9,000
New +$3.54M 0.43% 72
2014
Q3
Sell
-7,500
Closed -$2.12M 87
2014
Q2
$2.12M Hold
7,500
0.38% 69
2014
Q1
$2.25M Buy
+7,500
New +$2.31M 0.52% 57

Other funds holding REGN

Rock Springs Capital Management's REGN Position: Q2 2026 in Review

Rock Springs Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 10,100 shares — an estimated $7.8M sold.

Rock Springs Capital Management first reported a position in REGN in Q1 2014 and held it in 19 quarters. The position peaked at $7.86M in Q2 2017. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Rock Springs Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Rock Springs Capital Management sold 10,100 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $7.8M.
  • Rock Springs Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 19 quarters.
  • Rock Springs Capital Management's Regeneron Pharmaceuticals position peaked at $7.86M in Q2 2017.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.